摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-甲氧基苄氧基)-3-溴-4-甲基吡啶 | 1003312-15-9

中文名称
2-(4-甲氧基苄氧基)-3-溴-4-甲基吡啶
中文别名
——
英文名称
3-bromo-2-(4-methoxybenzyloxy)-4-methylpyridine
英文别名
2-(4-Methoxybenzyloxy)-3-bromo-4-methylpyridine;3-bromo-2-[(4-methoxyphenyl)methoxy]-4-methylpyridine
2-(4-甲氧基苄氧基)-3-溴-4-甲基吡啶化学式
CAS
1003312-15-9
化学式
C14H14BrNO2
mdl
MFCD26400388
分子量
308.175
InChiKey
NJYABRQDGDTFBT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.214
  • 拓扑面积:
    31.4
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Substituted pyridone compounds and methods of use
    申请人:Hu Essa
    公开号:US20080249090A1
    公开(公告)日:2008-10-09
    The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The compounds have a general Formula I wherein A 0-3 and R 1-6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
    本发明涉及一类新的化合物,能够调节c-kit受体,因此可用于治疗c-kit介导的疾病,包括各种炎症性、纤维化和/或肥大细胞介导的疾病,如肥大细胞增多症。该化合物具有一般的I式,其中A0-3和R1-6在此定义。本发明还涉及制药组合物、治疗c-kit介导的疾病的方法,以及制备本发明化合物的中间体和方法。
  • Substituted Pyridone Compounds and Methods of Use
    申请人:HU Essa
    公开号:US20100160312A1
    公开(公告)日:2010-06-24
    The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The compounds have a general Formula I wherein A 0-3 and R 1-6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
    本发明涉及一类新的化合物,能够调节c-kit受体,因此可用于治疗c-kit介导的疾病,包括各种炎症、纤维化和/或肥大细胞介导的疾病,如肥大细胞增多症。该化合物具有一般式I,其中A0-3和R1-6在此定义。本发明还涉及制药组合物、治疗c-kit介导疾病的方法,以及制备本发明化合物的中间体和方法。
  • Kinase inhibitors
    申请人:Allergan, Inc.
    公开号:US09321766B1
    公开(公告)日:2016-04-26
    The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    本发明涉及有机分子,能够调节酪氨酸激酶信号传导,以调节、调节和/或抑制异常细胞增殖。
  • INHIBITOR OF BRUTON'S TYROSINE KINASE
    申请人:Beijing Reciprocapharmaceuticals Co., Ltd.
    公开号:EP3882241A1
    公开(公告)日:2021-09-22
    Disclosed herein is a compound of Formula (I) with a Btk inhibitory activity, wherein all the variables are as defined herein. The compound can be used for the treatment of diseases such as autoimmune diseases, xenogeneic immune diseases, cancers or thromboembolic diseases. Also disclosed is a pharmaceutical composition comprising a compound of Formula (I). Futher provided is a compound capable of inhibiting the activity of Bruton's tyrosine kinase by covalent binding.
    本文公开了一种具有 Btk 抑制活性的式 (I) 化合物,其中所有变量如本文所定义。该化合物可用于治疗自身免疫性疾病、异种免疫性疾病、癌症或血栓栓塞性疾病等疾病。还公开了一种包含式(I)化合物的药物组合物。还提供了一种能够通过共价结合抑制布鲁顿酪氨酸激酶活性的化合物。
  • EP3882241
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多